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Abstract 
 Background&Aims: Polyglandular autoimmune syndrome (PAS) 
type II is the most common of the immunoendocrinopathy syndromes. It is 
characterized by the presence of autoimmune Addison disease in 
combination with thyroid autoimmune diseases, type 1 diabetes mellitus, 
primary hypogonadism, myasthenia gravis, and celiac disease. The purpose 
of this study is to determine the epidemiological aspects of PAS type II in a 
group of adults with thyroid diseases and diabetes mellitus (DM). Methods: 
The studied group was of 350 cases with an age between 18-79 years. The 
group of adults was subdivided according to the type of changes in the 
glycemic balance in 2 subgroups: DM type 1 represented by 60 cases 
(17.14%) and DM type 2 represented by 290 cases (82.86%). The methods 
of investigation were represented by clinical, imaging, biochemical, 
hormonal and immunological parameters. Results: The prevalence of PAS 
type II in the study group was 3.14% (100% F and 0% M, p<0.001, 
X2=11.18) and prevailed in middle – age women. PAS type II prevalence in 
DM type 1 was 11.66% and 1.38% in DM type 2 (p<0.001, X2=200.01). 
Conclusions: PAS type II has prevailed in females and in the group with 
DM type 1 due to autoimmune origin.  
 
Keywords: Diabetes mellitus, thyroid disease, polyglandular autoimmune 
syndrome type II, adults 
 
Introduction 
Polyglandular autoimmune syndrome (PAS) is made up of a group of 
autoimmune disorders of the endocrine glands (Kahaly, 2009). 
 Polygandular autoimmune syndrome type II (PAS II) is the most 
common of the immunoendocrinopathy syndromes. It is characterized by the 
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obligatory occurrence of autoimmune Addison disease in combination with 
autoimmune chronic thyroiditis and/or type 1 diabetes mellitus. Primary 
hypogonadism, myasthenia gravis, and celiac disease also are commonly 
observed in this syndrome. 
 The definition of the syndrome depends on the fact that if one of the 
component disorders is present, an associated disorder occurs more 
commonly than in the general population. The most frequent clinical 
combination association is Addison disease and Hashimoto thyroiditis, while 
the least frequent clinical combination is Addison disease, Graves’s disease, 
and type 1 diabetes mellitus. 
The complete triglandular syndrome is sometimes referred to as 
Carpenter syndrome.  
 In United States, approximately 14-20 people per million populations 
are affected by polyglandular autoimmune syndrome type II. Observations 
have revealed, however, that the disease is much more prevalent if 
subclinical forms are included.  
 PAS II occurs primarily in adulthood, usually around the third and 
fourth decades of life. Middle-aged women have shown an increased 
prevalence of PAS II. The female-to-male ratio of polyglandular 
autoimmune syndrome type II is 3-4:1. To date, the mortality and morbidity 
rates of PAS II have not been clinically estimated. The mortality and 
morbidity of PAS II are believed to equal the mortality and morbidity of the 
individual component disorders. It is associated with HLA-DR3 and/or 
HLA-DR4 haplotypes, and the pattern of inheritance is autosomal dominant 
with variable expressivity (Obermayer-Straub et al, 1998).  
The autoimmune syndrome disorders present usually a long 
prodromal phase and the antibodies are present prior to the development of 
the disorder. 
Autoimmunity, environmental factors, and genetic factors are the 3 
major factors that should be considered in the physiopathology of PAS II.  
The pathogenesis of polyglandular autoimmune syndrome type II is 
poorly understood (Baker, 1997, Betterle et al, 2004). The persons have 
some degrees of genetic susceptibility and than they are exposed to the 
autoimmune trigger, which could be an environmental or intrinsic factor 
(Ramos-Lopez et al, 2008). The trigger mimics the molecular structure of a 
self-antigen. An alternative explanation is that a breakdown in normal 
immunologic tolerogenesis occurs.  
Next, a subclinical phase of active production of organ-specific 
autoantibodies occurs. This phase is followed by autoimmune activity in the 
respective organ, in which there is progressive glandular destruction. The 
individual is still asymptomatic. 
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Overt clinical disease subsequently develops when extensive organ 
damage, caused by the aforementioned autoimmune activity, has occurred. 
Evidence of this autoimmune phenomenon that may be responsible for this 
syndrome is based on whether the affected organs demonstrate a chronic 
inflammatory infiltrate composed of lymphocytes (mainly) (Obermayer-
Straub et al, 1998). 
 Two other related autoimmune endocrinopathies exist, namely type I 
and type III.   
Polyglandular autoimmune syndrome type I (PAS I) is an autosomal 
recessive disorder caused by a mutation in the short arm of chromosome 21, 
characterized by the triad: muco-cutaneous candidiasis, hypoparathyroidism 
and Addison’s disease.  
The symptoms and signs appear in childhood; candidiasis is usually 
the first sign, followed usually by hypoparathyroidism and Addison disease 
(Myhre et al, 2001, Aldasouqi et al, 2006). DM type 1 occurs in less than 4% 
of affected children, but increases to 12% by adults. 
Polyglandular autoimmune syndrome type III (PAS III) (Aung et al, 
2006) is a PAS II syndrome, but without the adrenocortical involvement. It 
comprises a group of autoimmune disorders characterized by severe 
glandular insuffiency. A quarter of the patients with hypo functional glands 
present other endocrine diseases as well. This syndrome is associated with 
diseases as:  organ-specific autoimmune diseases (celiac disease, 
hypogonadism, and myasthenia gravis), organ-nonspecific or systemic 
autoimmune diseases (sarcoidosis, Sjogren syndrome, and rheumatoid 
arthritis), other diseases (gastric carcinoid tumor, malabsorption due to 
exocrine pancreatic deficiency), and may be classified into the following 3 
subcategories: 
• PAS III A – Autoimmune thyroiditis with immune-mediated diabetes 
mellitus  
• PAS III B - Autoimmune thyroiditis with pernicious anemia 
• PAS III C - Autoimmune thyroiditis with vitiligo and/or alopecia 
and/or other organ-specific autoimmune disease 
 
Material And Method 
Method 
Investigated Population 
350 people with DM (307 F and 43 M), aged between 18 and 79 
years represented the studied group. 
Depending on glycemic balance, the group was divided into:  
- the group with DM type 1 – 60 (17, 14%) (55 F and 5 M) 
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- the group with DM type 2 – 290 (82, 86%) (252 F and 38 M) 
Fig. 1. Cases classification depending on glycemic balance 
 
Methods Of Investigation  
The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated hemoglobin, 
investigation of the thyroid gland: TSH, FT4, FT3, thyroid antibodies, 
investigation of the adrenal gland: ACTH, 21-hydroxylase antibodies, 
gonadotropins: FSH, LH and appropriate sex hormones (testosterone, 
estradiol), investigation of celiac disease: antitissue transglutaminase 
antibodies, investigation of pernicious anemia: complete blood count with 
mean cell volume and vitamin B12 levels, parietal cell and anti-intrinsic 
factor antibodies.  
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the OGTT at 2 h between 140 
- 200 mg% and impaired fasting glucose - values between 110 - 125 mg% 
and OGTT at 2 h under 140 mg%.  
Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
To determine the TSH level in plasma, the free fraction of 
triiodotironin (FT3), and the plasma free fraction of thyroxin (FT4) were 
performed a quantitative method ARCHITECT; witch is an immunological 
method, Chemilumnescent Microparticle Immunoassay (CMIA). Normal 
values were following: TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, 
FT4 = 10-28.2 pmol/l.  
To obtain the level of cortisol was performed the technique 
IMMULITE / IMMULITE 1000, an imunometric method, in solid phase, 
competitive, of chemiluminescent, Immuno Chemilumino Enzymometric 
assay (ICEM). It was considered normal: a.m. 5-25 microgram/dl.  
17,14% 
82,86% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
DM type 1 DM type 2
C
as
e p
re
va
le
nc
e 
European Scientific Journal   January 2014  edition vol.10, No.3  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
35 
 
FSH level was measured quantitatively by the ARCHITECT method; 
a Chemilumnescent Microparticle Immunoassay. Reference values: 
determined with ARCHITECT test. 
Table I. The reference values for FSH 
Population field mIU/ml 
Women: 
- Follicular phase 
- Ovulating phase 
- Luteal phase 
- Postmenopausal 
 
3.35 – 21.63 
4.97 – 20.82 
1.11 – 13.99 
2.58 – 150.53 
Men 1.37 – 13.58 
 
LH level was measured quantitatively by the ARCHITECT method; a 
Chemilumnescent Microparticle Immunoassay. Reference values: 
determined with ARCHITECT test. 
Table II. The reference values for LH 
Population field mIU/ml 
Women: 
- Follicular phase 
- Ovulating phase 
- Luteal phase 
- Postmenopausal 
 
1.26 – 10.05 
2.57 – 26.53 
18.06 – 90.23 
0.67 – 23.75 
Men 1.09 – 92.45 
 
Testosterone was determinate by ELISA method. The references 
values are depending by age and gender: 
Adults: 
- men: 0.019-0.145 nmol/L; 
- women in fertile period: <0.014 nmol/L; 
- pills: 0.001-0.0069 nmol/L; 
- postmenopausal: 0.0003-0.0058 nmol/L. 
Estradiol was determinate by immunochemical with 
electrochemiluminiscent detection method (ECLIA). The references values 
are depending by age and gender, and at women also with the menstrual 
cycle period and pregnancy.  
Table III. The reference values for estradiol 
Age and gender References values (pmol/L) 
Adults – Women •  Follicular phase 
• Ovulating phase 
• Luteal phase 
• postmenopausal 
– Men 
46.0-607 
315-1828 
161-774 
<18.4-201 
28.0-156 
Pregnancy (first quarter) 789 – 15781 
Children (1-10 years) • girls 
• boys 
22.0-99.1 
<18.4-99.1 
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The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antiTPO and antiTg antibodies).  
To determine serum levels of antiTPO antibodies it was used the kit 
AxSYM antiTPO, an immunological method (Microparticle Enzyme 
Immunoassay) (MEIA). Normal values:  antiTPO antibodies <35 IU/ml.  
To determine serum levels of antiTg antibodies it was used the kit 
AxSYM antiTg, a MEIA method as well (Microparticle Enzyme 
Immunoassay). Normal values: antiTg antibodies <55 IU/ml.  
To determine 21-hydroxylase (anti 21-OH antibodies) antibodies 
level it was used the radioimunodetermination method combined with a 
technique of imunoprecipitation, based on human 21-OH marked with I 125 
reacting with the antibodies anti 21-OH from the samples test and forming 
immune complexes that precipitated with the solid-phase of protein A. 
Normal range: <1 IU/ml  
ACTH was determinate by immunoassay with chemiluminescent 
detection method.  
Antitissue transglutaminase antibodies were determinate by ELISA 
method. References values: IgA, IgG : <10 U/mL: negative;  ≥10 U/mL: 
positive. 
 Vitamin B12 levels were determinate by immunochemical with 
electrochemiluminiscent detection method (ECLIA). References values: 191-
663 pmol/L (for European population). 
Parietal cell antibodies were determinate by indirect 
immunofluorescence. References values: negative. 
Anti-intrinsic factor antibodies were determinate by ELISA method.  
References values: < 6 U/mL: negative. 
Determination of complete blood count was achieved with automatic 
method: electric impedance method. Normal values:  erythrocytes = 4-5.5 
mil/mm3 (men: 4.9 ± 0.7 mil/mm3, women: 4.3 ± 0.6 mil/mm3), leucocytes = 
5000 – 9000 mil/mm3, plateled = 150000 – 350 000/mm3, hematocrit (Ht): 
men 45 ± 7%, women 42 ± 5%, hemoglobin (Hb): men: 15 ± 2 g/dl, women: 
14 ± 2 g/dl.  
Constants and red cell indices are calculated automatically, 
depending on the values of Hb, Ht and red blood cells (RBC) count. Normal 
values: mean corpuscular volume (MCV) = 80-100 fl, mean corpuscular 
hemoglobin concentration (MCHC) = 32-36 g Hb/100 ml erythrocytes, mean 
corpuscular hemoglobin (MCH) = 27-32 pg.  
Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
An increased density, uniform, characterizes normal thyroid parenchyma 
easily distinguished from the neck muscles that are hypo dens.  
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Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
Chronic autoimmune thyroid disorder appears with a hypoecogenity 
of the parenchyma and normal or increased thyroid volume.  
 
Statistical Analysis 
For statistical analysis we used Microsoft Excel and POP Tools from 
Microsoft Office 2003 and EPI 2000 program. To measure the quantitative 
variables were determined average (A) and standard deviation (SD), and to 
assess the gender differences we used the unpaired t test and ANOVA test, 
considering statistically significant a p < 0.05. 
 
Results And Discussion 
In the group of adults 17.14% had DM type 1 and 82.86% had DM 
type 2.  
The prevalence of PAS II in the study group was 3.14 % (11.66% in 
the case of DM type 1 and 1.38% in the case of DM type 2, p < 0.001, X2 = 
200.01). (Table IV).  
Table IV. Prevalence of PAS II in the study group 
Associations Subject group 
No. % 
DM type 1 60  
DM type 1 + ACT + asimtomatic Addison disease 7 11.66% 
DM type 2 290  
DM type 2 + ACT + Addison disease 4 1.38% 
In adults with type 1 diabetes mellitus, the prevalence of PAS II was 
11.66%. All were women, with a medium age 44.28 ± 23.57 years. We don’t 
find family history of thyroid diseases or diabetes.   
In the study group, all patients had DM type 1 clinically manifest, all 
being treated with insulin in different therapeutic schemes. 
In 2 cases, the first disease was DM type 1; follow by ACT after 2 ± 
0.5 years. In 5 cases, the first disease was ACT; follow by DM type 1 after 
27.8 ± 23.13 years.  
For appreciation association of Addison disease, were determinate 
plasma cortisol and 21-OH antibodies. The 21-OH values were significally 
higher in 7 cases, all theses were clinically asymptomatic.  
In adults with type 2 diabetes mellitus, the prevalence of PAS II was 
1.38 %. All were women, with a medium age 61.75 ± 7.32 years, and the 
onset medium age for thyroid disease was 60.75 ± 8.38 years. We don’t find 
family history of thyroid diseases or diabetes. 
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At all patients with DM type 2 the treatment was diet. 
All the 4 cases with Addison diseases were symptomatic; the 
diagnosis was early, base on clinical symptoms. In the case of association 
between Addison disease and ACT, the first imunophathy was Addison 
disease; follow after 10 - 16 years by ACT.  
In general, in the first stage of PAS antibodies levels are elevated. In 
the second stage the disease is sub clinical and in the third stage becomes 
clinically manifested.  
In the case of association of Addison disease, the substitution 
treatment may determinate unbalance of DM, especially of DM type 1 
(Betterle et al, 2004). 
Among patients with type 1 diabetes mellitus, thyroid autoimmunity 
and celiac disease coexist with sufficient frequency to justify screening. 
Measuring annual thyrotropin levels in individuals with type 1 diabetes 
mellitus is recommended as cost-effective.  
Clinical history and examination suggesting evidence of more than 1 
endocrine deficiency should prompt testing, to include serum autoantibody 
screening and an evaluation of end-organ function.  
Serum auto antibodies screen – this helps to verify the autoimmune 
etiology of the disease and to identify persons who may later develop multi-
endocrine deficiency. This test also is useful in screening asymptomatic 
family members who may develop autoimmune endocrine disease in the 
future.  
Evaluation of end-organ function is necessary to confirm the 
diagnosis in patients with positive auto antibodies. Even if these antibodies 
are negative, still perform testing if clinical suspicion is high, because the 
sensitivity of these assays is not perfect. Some of these tests must be perform 
annually, because not all diseases manifest at the time of the initial diagnosis. 
(Sivarajah et al, 2006) 
The treatment of patients with PAS involves early identification of all 
components.  
The treatment of PAS is currently the treatment of each component of 
endocrine disorder (usually through hormone substitution therapy).  
Isohormonal therapy has "immunomodulatory” capacities (hormone 
produced by the target organs may be able to influence autoimmunity).  
Associations of specific autoimmune endocrinopathys require 
specific management. The substitution treatment with thyroxin may 
precipitate the adrenal insufficiency in the case of untreated Addison disease. 
Hypoglycemia or decrease of insulin requirement at patients with DM type 1 
may signified the onset of the adrenal insufficiency. The asymptomatic 
forms of Addison disease must be treating with attention in acute stress 
condition. In Addison disease associate with ovarian insufficiency, the 
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substitution therapy with steroid hormones may prevent severe osteoporosis.  
Controversial discussions are described in the literature on the effectiveness 
of thyroxin in patients with positive antibodies, but with euthyroidism or sub 
clinical hypothyroidism (Hossein et al, 2005).  
Some show a significant reduction of the TSH and of the anti-TPO 
antibodies in patients with autoimmune thyroiditis and euthyroidism after 1 
year of treatment with thyroxin (Hossein et al, 2005).  
The PAS classification is not final. This may change over time, with 
the onset of new endocrine disorders or associations with new autoimmune 
determination.  
Ideal is to determine the presence of antibodies, especially in DM 
type 1, because they may be present by subjects without clinical symptoms. 
If their levels are raised, it is good to monitor annual the TSH level and if it 
is normal it is recommended to doze antithyroid antibodies by intervals of 2-
3 years (Eisenbarth et al, 2004, Tunbridge et al, 2000).  
Also, if the disease is autoimmune, the patient should be investigated 
for other autoimmune associations of endocrine or no endocrine nature.  
A study in Czech Republic on 51 patients with DM type 1 showed 
that it is associated with autoimmune thyroid diseases, with Addison’s 
disease and celiac disease. 
The authors recommend finding the specific antibodies for each 
disease, to diagnose the disease in the initial phase, and to prevent the 
complications that will affect the quality of the patients’ life (Gonem et al, 
2007).  
If DM type 2 is present it is recommended to evaluate TSH levels, 
and if it is normal, to repeat this evaluation every 5 years.  
If pre-existing thyroid pathology is present it is recommended to 
evaluate plasma glucose levels annually.  
The time course of the development of organ-specific autoimmunity 
makes it necessary to repeatedly reevaluate patients and their families over 
time. Provocative and suppressive testing frequently is necessary. (De Graaff 
et al, 2007, Förster et al, 1999).  
 
Conclusion 
The prevalence of PAS type II in the study group was 3.14%; all the 
patients with this were middle-aged women.  
PAS type II has prevailed in the group with type 1 diabetes due to 
autoimmune origin.  
Many disorders involved in PAS present a long prodromal phase, 
characterized by the presence of characteristics antibodies for each disorder 
in part, before the clinical manifestations.  
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So, if we have a patient with two or more autoimmune disease, we 
must investigate this and the asymptomatic family members for another 
possible autoimmune disease, using cost-effective tests. 
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